Table 2 Univariate and Multivariate Analysis of Prognostic Factors for Overall Survival and Time-to-Progression of Disease
Prognostic Factor | Parameters Compared | Overall Survival (OS) | Time to Progression (TTP) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | ||||||
HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | ||
Age | >65 vs. ≤65 years | 1.13 (0.44–2.94) | 0.12 | N/A | – | 1.14 (0.44–2.95) | 0.80 | N/A | – |
Gender | Male vs. Female | 1.28 (0.41–3.98) | 0.67 | N/A | – | 1.19 (0.39–3.66) | 0.76 | N/A | – |
Comorbidity | Present vs. Absent | 0.80 (0.26–2.45) | 0.69 | N/A | – | 0.98 (0.32–3.00) | 0.97 | N/A | – |
Portal Vein Thrombosis | Main vs. Branch Portal Vein | 1.70 (0.55–5.25) | 0.36 | N/A | – | 1.68 (0.55–5.17) | 0.37 | N/A | – |
Occlusive vs. non-occlusive | 1.23 (0.39–3.82) | 0.72 | N/A | – | 1.19 (0.39–3.66) | 0.76 | N/A | – | |
Tumor Size | >10 vs. ≤10 cm | 1.02 (0.39–2.65) | 0.97 | N/A | – | 0.89 (0.34–2.31) | 0.81 | N/A | – |
Tumor Volume | >500 vs. ≤500 cm3 | 1.34 (0.48–3.43) | 0.87 | N/A | – | 1.12 (0.73–3.15) | 0.72 | N/A | – |
Tumor Extent | Unilobar vs. Bilobar | 1.02 (0.38–2.77) | 0.96 | N/A | – | 1.08 (0.40–2.93) | 0.88 | N/A | – |
Solitary vs. Multifocal | 1.43 (0.61–4.15) | 0.76 | N/A | – | 1.12 (0.43–2.17) | 0.69 | N/A | – | |
Portal Hypertension | Present vs. Absent | 2.69 (0.77–9.40) | 0.12 | N/A | – | 2.53 (0.73–8.80) | 0.146 | N/A | – |
Encephalopathy | Present vs. Absent | 1.45 (0.33–6.44) | 0.62 | N/A | – | 1.38 (0.31–6.05) | 1.38 | N/A | – |
ECOG PS | 0 vs. 1–2 | 16.17 (2.06–126.83) | 0.018 | 11.29 (1.92–19.06) | 0.021 | 13.01 (1.69–100.4) | 0.016 | 13.52 (1.65–175.27) | 0.004 |
Child Pugh Class | A vs. B | 8.21 (2.59–26.04) | 0.006 | 6.32 (1.79–16.55) | 0.013 | 7.07 (2.17–23.00) | 0.009 | 12.31 (2.58–59.23) | 0.005 |
Alpha-fetoprotein | >400 vs. ≤400 ng/dl | 1.12 (0.43–2.97) | 0.82 | N/A | – | 1.06 (0.40–2.78) | 0.911 | N/A | – |
Lung Shunt Fraction | >10% vs. ≤10% | 4.89 (1.55–15.63) | 0.004 | 6.42 (1.96–10.31) | 0.029 | 3.91 (1.33–11.36) | 0.013 | 7.91 (3.06–17.48) | 0.011 |
Treatments prior to Y-90 | Yes vs. No | 1.67 (0.37–3.18) | 0.35 | N/A | – | 1.74 (0.51–2.93) | 0.41 | N/A | – |
Baseline MCS | Within 2SD vs. >2SD below of NBS | 1.25 (0.22–2.57) | 0.38 | N/A | – | 1.18 (0.77–3.68) | 0.36 | N/A | – |
Baseline PCS | Within 2SD vs. >2SD below of NBS | 1.38 (0.66–3.39) | 0.58 | N/A | – | 1.29 (0.93–3.17) | 0.19 | N/A | – |
MCS at 1 month post-Y90 | Within 2SD vs. >2SD below of NBS | 2.24 (0.98–3.98) | 0.17 | N/A | – | 2.13 (0.53–3.66) | 0.83 | N/A | – |
PCS at 1 month post-Y90 | Within 2SD vs. >2SD below of NBS | 2.59 (1.04–4.23) | 0.026 | 1.73 (1.02–3.18) | 0.041 | 2.03 (1.13–4.57) | 0.023 | 3.28 (1.48–5.13) | 0.044 |
MCS at 3-months post-Y90 | Within 2SD vs. >2SD below of NBS | 1.87 (0.49–2.13) | 0.83 | N/A | – | 1.55 (0.90–2.98) | 0.88 | N/A | – |
PCS at 3 months post-Y90 | Within 2SD vs. >2SD below of NBS | 1.48 (0.86–3.02) | 0.44 | N/A | – | 1.47 (0.74–2.93) | 0.59 | N/A | – |
MCS at 6 months post-Y90 | Within 2SD vs. >2SD below of NBS | 1.44 (0.82–2.73) | 0.23 | N/A | – | 1.96 (0.42–4.13) | 0.38 | N/A | – |
PCS at 6-months post-Y90 | Within 2SD vs. >2SD below of NBS | 1.59 (0.92–2.11) | 0.71 | N/A | – | 1.37 (0.79–3.13) | 0.62 | N/A | – |